Heath Bulletin: National Tuberculosis Control Programme

Period: Q2 (April-Jun, 2025) Date of issue: 8th September, 2025

Tuberculosis continues to be one of the world's leading infectious diseases, affecting millions of individuals each year. Despite being preventable and curable, TB remains a significant public health challenge, particularly in low and middle income countries. The National Tuberculosis Control Program plays a vital role in coordinating efforts to detect, treat and prevent TB, with a strong emphasis on community awareness, early diagnosis and sustained treatment adherence.

This health bulletin aims to provide an overview of recent developments, progress and challenges in the fight against TB. It serves a platform to share updates from the field, highlight success stories, and showcase innovations in diagnosis and treatment and reinforce our collective commitment to eliminate TB as a public health threat.



Fig 1: Quarter wise National CNR from 1st Q 2024 to 2nd Q 2025



Fig 2: The division wise comparison of Case Notification Rate (CNR) during 1st Q and 2nd Q 2025.

Barisal division has the highest CNR among all the division which is 211 though in this division this CNR was 216 during 1st Quarter 2025.



Fig 3: The type of cases in 2nd Quarter, 2025

Based on the types of cases PBC, PCD and EP account for 62%, 15% and 23% respectively indicating that PBC cases are the most prevalent.



Fig 4: Comparison of Quarter wise Child TB Notification

The child TB data indicates a decline in cases during the first quarter of 2025, followed by a return to the previous trend in the second Quarter.



Fig 5: Quarter-wise TPT Status

The analyzed data indicates that in the first quarter 2024, 63% of eligible individuals were enrolled in TPT. However in the second quarter of 2024 the data shows an increasing trend with the enrollment rate increasing to 79% by the second quarter 2025.

Laboratory Network Strengthening

By the end of the 2nd Quarter of 2025, NTP has significantly expanded its molecular diagnostic capacity with 840 Xpert and 150 Truenat machines deployed nationwide. Currently, 146 Xpert laboratories are providing MTB XDR testing marking a major advancement in the Drug Susceptibility Testing (DST) capacity of the NTP laboratory network.

To strengthen quality assurance, NTP has successfully completed capacity building for in-country production of panels to support External Quality Assurance (EQA) of molecular tools. Three batches of specialized training were conducted under the TGF-supported project implemented by FIND within a period of five months. Beginning in August 2025, piloting will commence across 50 Xpert Ultra, 20 MTB XDR and 30 Truenat sites, an achievement of historic significance for TB diagnostics in Bangladesh.

In parallel, two batches of TBSLMTA (Strengthening Laboratory Management toward Accreditation) workshops have been completed and mentorship visits were conducted across all six TB reference laboratories. Building on these milestones, NTP is now preparing to apply for ISO 15189 accreditation by October 2025, taking a decisive step toward meeting international quality standards

Events, Workshops for NTP during 1st Quarter 2025

1. A Meeting was held with MIS DGHS to review the Current Status of TB Data within DG MIS System (Data Quality Management) on 5th May 2025 at 11:30.

2. Divisional Review meeting on mWRD (GeneXpert and Truenat) site monitoring was held on 26th June 2025.

Conclusion

The fight against TB continues to gain momentum through strengthened prevention, early detection and treatment efforts. However to reach the goal of ending TB, sustained commitment, investment and innovation are essential. The NTP program remains dedicated to closing gaps in care, protecting vulnerable populations, working towards a TB free future for all.